ALC News and Press, Alcon Inc. From 11/09/21

Alcon (NYSE:ALC) swung to net income of $2M in Q3 2021 from a loss of $147M in prior-year due in part to a boost in sales in its surgical business. Sales in that division were ~1.2B, a ~17% increase compared to Q3 2020. Vision care sales rose ~12% to $923M. R&D expenses increased 47% to 3...

Alcon (NYSE:ALC): Q3 Non-GAAP EPS of $0.54 beats by $0.03; GAAP EPS of $0.00 misses by $0.15. Revenue of $2.08B (+14.3% Y/Y) beats by $30M. Shares -2%. Press Release For further details see: Alcon EPS beats by $0.03, beats on revenue

Third quarter sales of $2.1 billion, up 15% or 14% constant currency Continued growth in all Surgical and Vision Care categories versus 2020, driven by innovation, commercial execution and market recovery Nine months cash from operations of $958 million and...

Alcon (NYSE:ALC) is scheduled to announce Q3 earnings results on Tuesday, November 9th, after market close. The consensus EPS Estimate is $0.50 (+28.2% Y/Y) and the consensus Revenue Estimate is $2.04B (+12.1% Y/Y). Over the last 2 years, ALC has beaten EPS estimates 75% of the time and has b...

SMART Solutions by Alcon, a digital platform uniquely designed for ophthalmology, builds on Alcon leadership in image-guided clinic to OR connectivity through cloud-based planning and surgical equipment Installs of first application, SMARTCataract, are underway with U.S. cus...

Alcon (NYSE:ALC) has acquired Ivantis, developer and manufacturer of the novel Hydrus Microstent, a minimally-invasive glaucoma surgery (MIGS) device designed to lower intraocular pressure for open-angle glaucoma patients in connection with cataract surgery. The deal involves $475M in up...

Expands Alcon’s leading surgical portfolio and leverages the company’s commercial execution expertise Strong safety and efficacy profile evidenced by five-year study on Hydrus Microstent, a minimally invasive glaucoma surgery (MIGS) device Indicated to ...

TOTAL30 contact lenses to be showcased at the conference through in-booth lens try-on, an exclusive launch event for eye care professionals, scientific data presentations and more Numerous clinical presentations to affirm the efficacy of Alcon’s portfolio of contact lenses ...

ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. The Strategy was held back by weakness among our emerging...

Alcon associates across 43 global sites take the Steps for Sight challenge, raising funds to support organizations improving access to quality eye care Alcon Geneva associates will dedicate the day to learning more about the importance of eye health, including onsite vision ...